DUBLIN, July 30, 2021--(BUSINESS WIRE)--The "Global Neoantigen Cancer Vaccine Market, By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
The Global Neoantigen Cancer Vaccine Market is projected to grow with a CAGR of 54.18% during the forecast period and is expected to reach USD 1754.44 million by 2026.
The key factors responsible for the growth of neoantigen cancer vaccine market include rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to boost the growth of neoantigen cancer vaccine market across the globe in the coming years.
The Global Neoantigen Cancer Vaccine Market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region, and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment is expected to dominate the market through 2026 and intramuscular is anticipated to be the fastest growing segment in the forecast period.
This growth can be accredited to quick response as well as to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment in the coming years.
The application segment is further segregated into lung, melanoma, gastrointestinal, brain cancer, and others. The lung cancer segment is going to dominate the market in the forecast period as the neoantigen based immunotherapy of OSE Immunotherapeutic, which is in development for the Tedopi (OSE2101) neoantigen cancer vaccine is expected to launch in 2022. Tedopi (OSE2101), is used in the treatment of HLA-A2+ Lung cancer (NSCLC) patients. Currently, the vaccine is in phase III stage of clinical development.
Regionally, Asia Pacific neoantigen cancer vaccine market is expected to be the leading region over the forecast period due to the rising prevalence and incidence of cancer cases including lung cancer, melanoma, gastrointestinal, pancreatic cancer and other solid tumor indications.
Major companies operating in the market across the globe are focusing more towards expanding their share in the market.
Major players operating in the Global Neoantigen Cancer Vaccine Market include
OSE Immunotherapeutics SA
Gritstone bio, Inc
F Hoffmann-La Roche Ltd
Merck & Co Inc
Avidea Technologies, Inc
Eli Lilly and Company
Novogene Co, Ltd
ZIOPHARM Oncology Inc
ISA Pharmaceuticals BV
BrightPath Biotherapeutics Co, Ltd
Genocea Biosciences Inc
Years considered for this report:
Base Year: 2020
Estimated Year: 2022
Forecast Period: 2023-2026
Global Neoantigen Cancer Vaccine Market, By Product:
Personalized neo-antigen vaccine
Off-the shelf neoantigen vaccine
Global Neoantigen Cancer Vaccine Market, By Neoantigen Type:
Synthetic Long Peptide
Global Neoantigen Cancer Vaccine Market, By Route of Administration:
Global Neoantigen Cancer Vaccine Market, By Cell:
Global Neoantigen Cancer Vaccine Market, By Technology:
Whole Genome Sequencing
Global Neoantigen Cancer Vaccine Market, By Delivery Mechanism:
Global Neoantigen Cancer Vaccine Market, By Application:
Global Neoantigen Cancer Vaccine Market, By Region:
Middle East and Africa
For more information about this report visit https://www.researchandmarkets.com/r/2z9kl5
View source version on businesswire.com: https://www.businesswire.com/news/home/20210730005248/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900